person · Reporting owner
Mubadala Investment Co PJSC
Disclosed activity across 7 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADVANCED MICRO DEVICES INCAMD · Entity 2796 | Director | February 05, 2019 | February 07, 2019 |
| MidCap Apollo Institutional Private LendingNONE · Entity 75251 | 10% owner | June 14, 2024 | September 11, 2025 |
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | 10% owner | March 02, 2023 | March 03, 2023 |
| Virgin Orbit Holdings, Inc.VORB · Entity 114569 | 10% owner | December 30, 2021 | January 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADVANCED MICRO DEVICES INC
Report date February 05, 2019 · Filed February 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 75,000,000 |
Last balance in matching sequence
After 2019-02-05 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2019-02-05 · Sale · Disposed 34,906,166 · Balance 0 F1: The shares are held on behalf of the Reporting Person by West Coast Hitech L.P., a Cayman Islands limited partnership wholly-owned and controlled by the Reporting Person. West Coast Hitech G.P., Ltd. is a Cayman Islands corporation wholly-owned and controlled by the Reporting Person that acts as the general partner of West Coast Hitech L.P. The business address of West Coast Hitech L.P. and West Coast Hitech G.P., Ltd. is P.O. Box 45005, Abu Dhabi, United Arab Emirates. Row 2 · 2019-02-05 · Other · Acquired 75,000,000 · Balance 75,000,000 F1: The shares are held on behalf of the Reporting Person by West Coast Hitech L.P., a Cayman Islands limited partnership wholly-owned and controlled by the Reporting Person. West Coast Hitech G.P., Ltd. is a Cayman Islands corporation wholly-owned and controlled by the Reporting Person that acts as the general partner of West Coast Hitech L.P. The business address of West Coast Hitech L.P. and West Coast Hitech G.P., Ltd. is P.O. Box 45005, Abu Dhabi, United Arab Emirates. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.98 · Expires 2020-02-29 | IndirectSee footnote | 0 |
Reported balance
After 2019-02-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-02-05 · Other · Disposed 75,000,000 · Balance 0 F3: The warrant was granted to a subsidiary of the Reporting Person as part of the consideration for a commercial agreement between the issuer and such subsidiary and were subsequently transferred to the Reporting Person by such subsidiary (see Exhibit 10.1 of AMD's Current Report on Form 8-K, filed on August 31, 2016). F2: The warrant became exercisable with respect to 50,000,000 shares of common stock of the issuer upon issuance of the warrant, however did not become exercisable with respect to 25,000,000 shares of common stock of the issuer until August 30, 2017. Exercise of the warrant will be settled with proceeds from the sale of Common Stock detailed in Table I. F1: The shares are held on behalf of the Reporting Person by West Coast Hitech L.P., a Cayman Islands limited partnership wholly-owned and controlled by the Reporting Person. West Coast Hitech G.P., Ltd. is a Cayman Islands corporation wholly-owned and controlled by the Reporting Person that acts as the general partner of West Coast Hitech L.P. The business address of West Coast Hitech L.P. and West Coast Hitech G.P., Ltd. is P.O. Box 45005, Abu Dhabi, United Arab Emirates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held on behalf of the Reporting Person by West Coast Hitech L.P., a Cayman Islands limited partnership wholly-owned and controlled by the Reporting Person. West Coast Hitech G.P., Ltd. is a Cayman Islands corporation wholly-owned and controlled by the Reporting Person that acts as the general partner of West Coast Hitech L.P. The business address of West Coast Hitech L.P. and West Coast Hitech G.P., Ltd. is P.O. Box 45005, Abu Dhabi, United Arab Emirates.
F2: The warrant became exercisable with respect to 50,000,000 shares of common stock of the issuer upon issuance of the warrant, however did not become exercisable with respect to 25,000,000 shares of common stock of the issuer until August 30, 2017. Exercise of the warrant will be settled with proceeds from the sale of Common Stock detailed in Table I.
F3: The warrant was granted to a subsidiary of the Reporting Person as part of the consideration for a commercial agreement between the issuer and such subsidiary and were subsequently transferred to the Reporting Person by such subsidiary (see Exhibit 10.1 of AMD's Current Report on Form 8-K, filed on August 31, 2016).
MidCap Apollo Institutional Private Lending
Report date June 14, 2024 · Filed September 11, 2025
Jointly reported with Mamoura Diversified Global Holding PJSC, MIC Capital Management 85 RSC Ltd
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares of Beneficial InterestSEC Table I · non-derivative | IndirectSee Footnote | 13,788,414 |
Reported balance
After 2024-06-14 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-06-14 · Purchase · Acquired 1,667,108 · Balance 13,788,414 F1: Amount reflects beneficial ownership of the Reporting Persons following the purchase of the common shares of beneficial interest ("Common Shares") of MidCap Apollo Institutional Private Lending reported herein and does not reflect a subsequent purchase that was previously reported. F2: Reflects securities held directly by MIC Capital Management 85 RSC Ltd, a wholly owned subsidiary of Mamoura Diversified Global Holding PJSC. Mamoura Diversified Global Holding PJSC is a wholly owned subsidiary of Mubadala Investment Company PJSC. |
Filing footnotes · ownership attribution and instrument terms
F1: Amount reflects beneficial ownership of the Reporting Persons following the purchase of the common shares of beneficial interest ("Common Shares") of MidCap Apollo Institutional Private Lending reported herein and does not reflect a subsequent purchase that was previously reported.
F2: Reflects securities held directly by MIC Capital Management 85 RSC Ltd, a wholly owned subsidiary of Mamoura Diversified Global Holding PJSC. Mamoura Diversified Global Holding PJSC is a wholly owned subsidiary of Mubadala Investment Company PJSC.
RECURSION PHARMACEUTICALS, INC.
Report date March 02, 2023 · Filed March 03, 2023
Jointly reported with Mamoura Diversified Global Holding PJSC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee Explanation of Responses | 12,985,927 |
Reported balance
After 2023-03-02 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2023-03-02 · Purchase · Acquired 66,822 · Balance 12,985,927 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.71 to $7.97, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Form 4. F2: Consists of 12,985,927 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is a wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee Explanation of Responses | 7,062,869 |
Reported balance
Holding disclosure · report date 2023-03-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,062,869 F3: MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP. F4: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.71 to $7.97, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Form 4.
F2: Consists of 12,985,927 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is a wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi.
F3: MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP.
F4: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
F5: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.
Virgin Orbit Holdings, Inc.
Report date December 30, 2021 · Filed January 10, 2022
Jointly reported with Fifteenth Investment Co LLC, Mamoura Diversified Global Holding PJSC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 60,175,111 |
Reported balance
Holding disclosure · report date 2021-12-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 60,175,111 F1: Fifteenth Investment Company LLC is the record holder of these shares. Mamoura Diversified Global Holding PJSC directly or indirectly wholly owns Fifteenth Investment Company LLC. Mamoura Diversified Global Holding PJSC is a wholly-owned subsidiary of Mubadala Investment Company PJSC. As a result, Mamoura Diversified Global Holding PJSC and Mubadala Investment Company PJSC may be deemed to have beneficial ownership of the shares directly held by Fifteenth Investment Company LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Fifteenth Investment Company LLC is the record holder of these shares. Mamoura Diversified Global Holding PJSC directly or indirectly wholly owns Fifteenth Investment Company LLC. Mamoura Diversified Global Holding PJSC is a wholly-owned subsidiary of Mubadala Investment Company PJSC. As a result, Mamoura Diversified Global Holding PJSC and Mubadala Investment Company PJSC may be deemed to have beneficial ownership of the shares directly held by Fifteenth Investment Company LLC.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Blue Owl Technology Finance Corp. II
Report date March 24, 2025 · Filed March 27, 2025
Jointly reported with Mamoura Diversified Global Holding PJSC, MIC Capital Management 85 RSC Ltd, MIC Capital Management 93 RSC Ltd
Section 16 reporting ended · disclosed 2025-03-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Explanation of Responses | 0 |
Reported balance
After 2025-03-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-03-24 · Other · Disposed 31,965,863.918 · Balance 0 F1: As of March 24, 2025, Blue Owl Technology Finance Corp. ( the "Issuer"), completed a merger by and among the Issuer, Blue Owl Technology Finance Corp. II, a Maryland corporation ("OTF II"), Oriole Merger Sub Inc., a Maryland corporation and wholly owned subsidiary of OTF ("Merger Sub"), and other parties thereto pursuant to the Agreement and Plan of Merger, dated as of November 12, 2024 ("Merger Agreement"). Pursuant to the Merger Agreement, Merger Sub was first merged with and into OTF II, with OTF II as the surviving corporation (the "Initial Merger"), and, immediately following the Initial Merger, OTF II was then merged with and into the Issuer, with the Issuer as the surviving company (the Initial Merger and the subsequent merger, collectively, the "Merger"). F2: The Reporting Persons are filing this exit Form 4 to report that it no longer a beneficially owns more than 10% of securities of the Issuer due to the Merger. F3: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: As of March 24, 2025, Blue Owl Technology Finance Corp. ( the "Issuer"), completed a merger by and among the Issuer, Blue Owl Technology Finance Corp. II, a Maryland corporation ("OTF II"), Oriole Merger Sub Inc., a Maryland corporation and wholly owned subsidiary of OTF ("Merger Sub"), and other parties thereto pursuant to the Agreement and Plan of Merger, dated as of November 12, 2024 ("Merger Agreement"). Pursuant to the Merger Agreement, Merger Sub was first merged with and into OTF II, with OTF II as the surviving corporation (the "Initial Merger"), and, immediately following the Initial Merger, OTF II was then merged with and into the Issuer, with the Issuer as the surviving company (the Initial Merger and the subsequent merger, collectively, the "Merger").
F2: The Reporting Persons are filing this exit Form 4 to report that it no longer a beneficially owns more than 10% of securities of the Issuer due to the Merger.
F3: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
Endeavor Group Holdings, Inc.
Report date March 24, 2025 · Filed March 27, 2025
Jointly reported with Mamoura Diversified Global Holding PJSC
Section 16 reporting ended · disclosed 2025-03-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2025-03-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-03-24 · Other · Disposed 2,232,747 · Balance 0 F1: On March 24, 2025, the previously announced acquisition of the Issuer was completed pursuant to the terms of the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), by and among the Issuer, Wildcat EGH Holdco, L.P., an affiliate of Silver Lake Group, L.L.C., and other parties thereto. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $27.50 in cash, without interest and subject to applicable withholding taxes, other than with respect to certain shares of the Issuer's common stock. F2: Reflects securities held directly by Fifteenth Investment Company LLC, a wholly owned subsidiary of Mamoura Diversified Global Holding PJSC. Mamoura Diversified Global Holding PJSC is a wholly owned subsidiary of Mubadala Investment Company PJSC. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 24, 2025, the previously announced acquisition of the Issuer was completed pursuant to the terms of the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), by and among the Issuer, Wildcat EGH Holdco, L.P., an affiliate of Silver Lake Group, L.L.C., and other parties thereto. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $27.50 in cash, without interest and subject to applicable withholding taxes, other than with respect to certain shares of the Issuer's common stock.
F2: Reflects securities held directly by Fifteenth Investment Company LLC, a wholly owned subsidiary of Mamoura Diversified Global Holding PJSC. Mamoura Diversified Global Holding PJSC is a wholly owned subsidiary of Mubadala Investment Company PJSC.
GAIA, INC
Report date December 04, 2018 · Filed May 14, 2019
Jointly reported with MDC Capital (Cayman) Ltd
Section 16 reporting ended · disclosed 2019-05-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,266,461 |
Reported balance
After 2018-12-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-12-04 · Purchase · Acquired 15,250 · Balance 1,266,461 F1: The Reporting Person inadvertently failed to report the acquisition of these shares at the time of acquisition. F2: 1,266,461 shares were held of record by MDC Capital (Cayman) Limited ("MDC Capital (Cayman)"), as trustee for Fifty First Investment Company LLC. MDC Capital (Cayman) is a direct wholly owned subsidiary of MDC Capital LLC. MDC Capital LLC, MDC Capital (Cayman) and Fifty First Investment Company LLC are controlled subsidiaries of Mubadala Development Company PJSC. Mubadala Development Company PJSC is wholly owned by Mubadala Investment Company PJSC. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2019-05-01 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-05-01 · Other · Disposed 1,266,461 · Balance 0 F3: On May 1, 2019, in connection with fund reorganization activities, the shares previously beneficially owned by the Reporting Persons were contributed to MIC Capital Partners (Public) Parallel Cayman, LP ("MIC Capital") in a non-cash transaction at a value of $10.58 per share (the "Contribution"). Following the Contribution, the Reporting Persons no longer had beneficial ownership of any shares of the Issuer, but may be considered to have pecuniary interest (without control) in certain shares held by MIC Capital (which such number of shares would be less than 10% of the outstanding class of shares). F2: 1,266,461 shares were held of record by MDC Capital (Cayman) Limited ("MDC Capital (Cayman)"), as trustee for Fifty First Investment Company LLC. MDC Capital (Cayman) is a direct wholly owned subsidiary of MDC Capital LLC. MDC Capital LLC, MDC Capital (Cayman) and Fifty First Investment Company LLC are controlled subsidiaries of Mubadala Development Company PJSC. Mubadala Development Company PJSC is wholly owned by Mubadala Investment Company PJSC. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person inadvertently failed to report the acquisition of these shares at the time of acquisition.
F2: 1,266,461 shares were held of record by MDC Capital (Cayman) Limited ("MDC Capital (Cayman)"), as trustee for Fifty First Investment Company LLC. MDC Capital (Cayman) is a direct wholly owned subsidiary of MDC Capital LLC. MDC Capital LLC, MDC Capital (Cayman) and Fifty First Investment Company LLC are controlled subsidiaries of Mubadala Development Company PJSC. Mubadala Development Company PJSC is wholly owned by Mubadala Investment Company PJSC.
F3: On May 1, 2019, in connection with fund reorganization activities, the shares previously beneficially owned by the Reporting Persons were contributed to MIC Capital Partners (Public) Parallel Cayman, LP ("MIC Capital") in a non-cash transaction at a value of $10.58 per share (the "Contribution"). Following the Contribution, the Reporting Persons no longer had beneficial ownership of any shares of the Issuer, but may be considered to have pecuniary interest (without control) in certain shares held by MIC Capital (which such number of shares would be less than 10% of the outstanding class of shares).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2025 Filed Jul 31, 2025 23:12 UTC | MidCap Apollo Institutional Private Lending NONE · Entity 75251 | PurchaseCommon shares of beneficial interest | 773,328 | $24.16 | $18,683,604.48 |
DisclosureSEC source: 0000950170-25-101063 · ownership.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner MIC Capital Management 85 RSC Ltd · CIK 0002006022 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 14,561,742 F1 · ownership.nature: Reflects securities held directly by MIC Capital Management 85 RSC Ltd, a wholly owned subsidiary of Mamoura Diversified Global Holding PJSC. Mamoura Diversified Global Holding PJSC is a wholly owned subsidiary of Mubadala Investment Company PJSC. Read SEC document |
| March 24, 2025 Filed Mar 27, 2025 16:37 UTC | Blue Owl Technology Finance Corp. II NONE · Entity 81482 | OtherCommon Stock | 31,965,863.918 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-046148 · ownership.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · Former 10% Owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · Former 10% Owner MIC Capital Management 85 RSC Ltd · CIK 0002006022 · Former 10% Owner MIC Capital Management 93 RSC Ltd · CIK 0002063187 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Explanation of Responses Disclosed balance after: 0 F1 · kind: As of March 24, 2025, Blue Owl Technology Finance Corp. ( the "Issuer"), completed a merger by and among the Issuer, Blue Owl Technology Finance Corp. II, a Maryland corporation ("OTF II"), Oriole Merger Sub Inc., a Maryland corporation and wholly owned subsidiary of OTF ("Merger Sub"), and other parties thereto pursuant to the Agreement and Plan of Merger, dated as of November 12, 2024 ("Merger Agreement"). Pursuant to the Merger Agreement, Merger Sub was first merged with and into OTF II, with OTF II as the surviving corporation (the "Initial Merger"), and, immediately following the Initial Merger, OTF II was then merged with and into the Issuer, with the Issuer as the surviving company (the Initial Merger and the subsequent merger, collectively, the "Merger"). F2 · kind: The Reporting Persons are filing this exit Form 4 to report that it no longer a beneficially owns more than 10% of securities of the Issuer due to the Merger. F1 · price: As of March 24, 2025, Blue Owl Technology Finance Corp. ( the "Issuer"), completed a merger by and among the Issuer, Blue Owl Technology Finance Corp. II, a Maryland corporation ("OTF II"), Oriole Merger Sub Inc., a Maryland corporation and wholly owned subsidiary of OTF ("Merger Sub"), and other parties thereto pursuant to the Agreement and Plan of Merger, dated as of November 12, 2024 ("Merger Agreement"). Pursuant to the Merger Agreement, Merger Sub was first merged with and into OTF II, with OTF II as the surviving corporation (the "Initial Merger"), and, immediately following the Initial Merger, OTF II was then merged with and into the Issuer, with the Issuer as the surviving company (the Initial Merger and the subsequent merger, collectively, the "Merger"). F1 · ownership.nature: As of March 24, 2025, Blue Owl Technology Finance Corp. ( the "Issuer"), completed a merger by and among the Issuer, Blue Owl Technology Finance Corp. II, a Maryland corporation ("OTF II"), Oriole Merger Sub Inc., a Maryland corporation and wholly owned subsidiary of OTF ("Merger Sub"), and other parties thereto pursuant to the Agreement and Plan of Merger, dated as of November 12, 2024 ("Merger Agreement"). Pursuant to the Merger Agreement, Merger Sub was first merged with and into OTF II, with OTF II as the surviving corporation (the "Initial Merger"), and, immediately following the Initial Merger, OTF II was then merged with and into the Issuer, with the Issuer as the surviving company (the Initial Merger and the subsequent merger, collectively, the "Merger"). F2 · ownership.nature: The Reporting Persons are filing this exit Form 4 to report that it no longer a beneficially owns more than 10% of securities of the Issuer due to the Merger. F3 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. Read SEC document |
| March 24, 2025 Filed Mar 27, 2025 06:18 UTC | Endeavor Group Holdings, Inc. EDR · Entity 11600 | OtherClass A Common Stock | 2,232,747 | $27.50 | $61,400,542.50 |
DisclosureSEC source: 0000950170-25-045701 · ownership.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · See Remarks Mamoura Diversified Global Holding PJSC · CIK 0001419351 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: On March 24, 2025, the previously announced acquisition of the Issuer was completed pursuant to the terms of the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), by and among the Issuer, Wildcat EGH Holdco, L.P., an affiliate of Silver Lake Group, L.L.C., and other parties thereto. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $27.50 in cash, without interest and subject to applicable withholding taxes, other than with respect to certain shares of the Issuer's common stock. F2 · ownership.nature: Reflects securities held directly by Fifteenth Investment Company LLC, a wholly owned subsidiary of Mamoura Diversified Global Holding PJSC. Mamoura Diversified Global Holding PJSC is a wholly owned subsidiary of Mubadala Investment Company PJSC. Read SEC document |
| June 14, 2024 Filed Sep 11, 2025 20:10 UTC | MidCap Apollo Institutional Private Lending NONE · Entity 75251 | PurchaseCommon Shares of Beneficial Interest | 1,667,108 | $25.95 | $43,261,452.60 |
DisclosureSEC source: 0000950170-25-114223 · ownership.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner MIC Capital Management 85 RSC Ltd · CIK 0002006022 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 13,788,414 F1 · balance_after: Amount reflects beneficial ownership of the Reporting Persons following the purchase of the common shares of beneficial interest ("Common Shares") of MidCap Apollo Institutional Private Lending reported herein and does not reflect a subsequent purchase that was previously reported. F2 · ownership.nature: Reflects securities held directly by MIC Capital Management 85 RSC Ltd, a wholly owned subsidiary of Mamoura Diversified Global Holding PJSC. Mamoura Diversified Global Holding PJSC is a wholly owned subsidiary of Mubadala Investment Company PJSC. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 16:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 66,822 | $7.82 | $522,354.26 |
DisclosureSEC source: 0001839882-23-005947 · rxrx-form4_030223.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,985,927 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.71 to $7.97, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Form 4. F2 · ownership.nature: Consists of 12,985,927 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is a wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 16:05 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 48,867 | $7.94 | $388,082.17 |
DisclosureSEC source: 0001387131-23-002722 · rxrx-form4_030123.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,919,105 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.84 to $7.97, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Form 4. F2 · ownership.nature: Consists of 12,919,105 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is a wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 16:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 815 | $7.97 | $6,495.55 |
DisclosureSEC source: 0001387131-23-002678 · rxrx-form4_022823.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,870,238 F1 · ownership.nature: Consists of 12,870,238 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is a wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F3 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F4 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 16:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 52,500 | $7.69 | $403,725.00 |
DisclosureSEC source: 0001387131-23-002560 · rxrx-form4_022723.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,869,423 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.57 to $7.81, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Form 4. F2 · ownership.nature: Consists of 12,869,423 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| February 24, 2023 Filed Feb 27, 2023 16:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 109,118 | $7.64 | $833,552.40 |
DisclosureSEC source: 0001839882-23-004972 · rxrx-form4_022423.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,816,923 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.56 to $7.86, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. F2 · ownership.nature: Consists of 12,816,923 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 16:08 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 51,864 | $7.79 | $403,792.36 |
DisclosureSEC source: 0001387131-23-002375 · rxrx-form4_022323.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,707,805 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.72 to $7.97, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. F2 · ownership.nature: Consists of 12,707,805 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| February 22, 2023 Filed Feb 23, 2023 16:26 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 50,941 | $7.83 | $399,015.76 |
DisclosureSEC source: 0001387131-23-002324 · rxrx-form4_022323.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,655,941 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.69 to $7.94, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4 F2 · ownership.nature: Consists of 12,655,941 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 16:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 94,418 | $7.74 | $731,125.78 |
DisclosureSEC source: 0001387131-23-002285 · rxrx-form4_022123.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,605,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.65 to $7.97, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4 F2 · ownership.nature: Consists of 12,605,000 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 16:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 63,382 | $7.71 | $488,985.79 |
DisclosureSEC source: 0001387131-23-002254 · rxrx-form4_021723.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,510,582 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.58 to $7.97, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. F2 · ownership.nature: Consists of 12,510,582 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 17:27 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 42,682 | $7.90 | $337,042.68 |
DisclosureSEC source: 0001387131-23-002226 · rxrx-form4_021623.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,447,200 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.84 to $7.97, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. F2 · ownership.nature: Consists of 12,447,200 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is a wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 16:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 6,300 | $7.95 | $50,059.80 |
DisclosureSEC source: 0001839882-23-003873 · rxrx-form4_021323.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,404,518 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.90 to $7.97, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4 F2 · ownership.nature: Consists of 12,404,518 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 16:10 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 32,474 | $7.97 | $258,837.26 |
DisclosureSEC source: 0001839882-23-003743 · rxrx-form4_021323.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,398,218 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.90 to $8.00, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4 F2 · ownership.nature: Consists of 12,398,218 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| February 10, 2023 Filed Feb 13, 2023 16:41 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 11,000 | $7.98 | $87,807.50 |
DisclosureSEC source: 0001387131-23-001898 · rxrx-form4_021023.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,365,744 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.90 to $8.00, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. F2 · ownership.nature: Consists of 12,365,744 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 16:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 600 | $7.97 | $4,782.00 |
DisclosureSEC source: 0001839882-23-002830 · rxrx-form4_020123.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,354,744 F1 · ownership.nature: Consists of 12,354,744 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F3 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F4 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 16:27 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 7,886 | $7.99 | $63,005.99 |
DisclosureSEC source: 0001387131-23-000851 · rxrx-form4_012623.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,354,144 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.95 to $8.00, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. F2 · ownership.nature: Consists of 12,354,144 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| January 25, 2023 Filed Jan 26, 2023 16:11 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 24,526 | $7.88 | $193,267.33 |
DisclosureSEC source: 0001839882-23-001552 · rxrx-form4_012523.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,346,258 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from $7.75 to $7.97, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. F2 · ownership.nature: Consists of 12,346,258 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| January 10, 2023 Filed Jan 13, 2023 16:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 69,518 | $7.72 | $536,845.80 |
DisclosureSEC source: 0001387131-23-000335 · rxrx-form4_011123.xml · nonDerivative · entry 11 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,321,732 F1 · date: This is an inadvertent late filing due to an administrative error. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.52 to $8.00, inclusive. F13 · ownership.nature: Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F15 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F16 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| January 09, 2023 Filed Jan 13, 2023 16:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 76,046 | $7.64 | $580,839.35 |
DisclosureSEC source: 0001387131-23-000335 · rxrx-form4_011123.xml · nonDerivative · entry 10 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,252,214 F1 · date: This is an inadvertent late filing due to an administrative error. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.43 to $8.00, inclusive. F13 · ownership.nature: Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F15 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F16 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| January 06, 2023 Filed Jan 13, 2023 16:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 68,953 | $7.41 | $510,610.76 |
DisclosureSEC source: 0001387131-23-000335 · rxrx-form4_011123.xml · nonDerivative · entry 9 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,176,168 F1 · date: This is an inadvertent late filing due to an administrative error. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.10 to $8.00, inclusive. F13 · ownership.nature: Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F15 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F16 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| January 05, 2023 Filed Jan 13, 2023 16:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 80,035 | $7.38 | $590,554.25 |
DisclosureSEC source: 0001387131-23-000335 · rxrx-form4_011123.xml · nonDerivative · entry 8 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,107,215 F1 · date: This is an inadvertent late filing due to an administrative error. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.75, inclusive. F13 · ownership.nature: Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F15 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F16 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| January 04, 2023 Filed Jan 13, 2023 16:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 91,892 | $7.80 | $716,877.06 |
DisclosureSEC source: 0001387131-23-000335 · rxrx-form4_011123.xml · nonDerivative · entry 7 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 12,027,180 F1 · date: This is an inadvertent late filing due to an administrative error. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.52 to $7.88, inclusive. F13 · ownership.nature: Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F15 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F16 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| January 03, 2023 Filed Jan 13, 2023 16:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 141,646 | $7.50 | $1,063,010.74 |
DisclosureSEC source: 0001387131-23-000335 · rxrx-form4_011123.xml · nonDerivative · entry 6 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 11,935,288 F1 · date: This is an inadvertent late filing due to an administrative error. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.37 to $7.83, inclusive. F13 · ownership.nature: Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F15 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F16 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| December 30, 2022 Filed Jan 13, 2023 16:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 99,754 | $7.55 | $753,621.52 |
DisclosureSEC source: 0001387131-23-000335 · rxrx-form4_011123.xml · nonDerivative · entry 5 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 11,793,642 F1 · date: This is an inadvertent late filing due to an administrative error. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.72, inclusive. F13 · ownership.nature: Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F15 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F16 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| December 29, 2022 Filed Jan 13, 2023 16:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 84,622 | $7.71 | $652,774.11 |
DisclosureSEC source: 0001387131-23-000335 · rxrx-form4_011123.xml · nonDerivative · entry 4 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 11,693,888 F1 · date: This is an inadvertent late filing due to an administrative error. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.25 to $7.91, inclusive. F13 · ownership.nature: Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F15 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F16 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| December 28, 2022 Filed Jan 13, 2023 16:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 71,299 | $7.18 | $511,898.30 |
DisclosureSEC source: 0001387131-23-000335 · rxrx-form4_011123.xml · nonDerivative · entry 3 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 11,609,266 F1 · date: This is an inadvertent late filing due to an administrative error. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.07 to $7.32, inclusive. F13 · ownership.nature: Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F15 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F16 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| December 27, 2022 Filed Jan 13, 2023 16:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 145,652 | $7.24 | $1,054,403.96 |
DisclosureSEC source: 0001387131-23-000335 · rxrx-form4_011123.xml · nonDerivative · entry 2 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 11,537,967 F1 · date: This is an inadvertent late filing due to an administrative error. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.12 to $7.61, inclusive. F13 · ownership.nature: Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F15 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F16 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| December 23, 2022 Filed Jan 13, 2023 16:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 100,378 | $7.52 | $754,420.97 |
DisclosureSEC source: 0001387131-23-000335 · rxrx-form4_011123.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 11,392,315 F1 · date: This is an inadvertent late filing due to an administrative error. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.70, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (12) to this Form4. F13 · ownership.nature: Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F15 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F16 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 16:08 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 2,551,020 | $9.80 | $24,999,996.00 |
DisclosureSEC source: 0001387131-22-010982 · rxrx-form4_102722.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 11,291,937 F1 · shares: On October 24, 2022, Recursion Pharmaceuticals, Inc. (the "Issuer") entered into a securities purchase agreement with Fifteenth Investment Company LLC, pursuant to which the Issuer agreed to issue, for an aggregate purchase price of $24,999,996.00, 2,551,020 shares of Class A Common Stock, $0.00001 par value per share (the "PIPE Shares") of the Issuer's common stock at a price of $9.80 per share. F2 · ownership.nature: Consists of (i) 11,291,937 shares held of record by Fifteenth Investment Company LLC and (ii) 0 shares held of record by Thirty Fifth Investment Company LLC, as a result of a transfer of 5,963,140 shares to Fifteenth Investment Company LLC. Both Fifteenth Investment Company LLC and Thirty Fifth Investment Company LLC are wholly owned subsidiaries of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 17:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSeries D Convertible Preferred Stock · Derivative | 5,963,140 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · derivative · entry 9 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 0 Underlying: Class A Common Stock · 5,963,140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F8 · price: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F8 · derivative.exercise_date: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F8 · derivative.expiration_date: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F2 · ownership.nature: Consists of (i) 2,777,777 shares held of record by Fifteenth Investment Company LLC and (ii) 5,963,140 shares held of record by Thirty Fifth Investment Company LLC. Both Fifteenth Investment Company LLC and Thirty Fifth Investment Company LLC are wholly owned subsidiaries of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 17:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSeries D Convertible Preferred Stock · Derivative | 745,392 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · derivative · entry 8 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 0 Underlying: Class A Common Stock · 745,392 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F8 · price: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F8 · derivative.exercise_date: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F8 · derivative.expiration_date: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F1 · ownership.nature: MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 17:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSeries C Convertible Preferred Stock · Derivative | 2,307,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · derivative · entry 7 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 0 Underlying: Class A Common Stock · 2,738,824 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The shares of Series C Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1.1869 basis automatically upon the closing of the initial public offering of the Issuer. F7 · price: The shares of Series C Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1.1869 basis automatically upon the closing of the initial public offering of the Issuer. F7 · derivative.exercise_date: The shares of Series C Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1.1869 basis automatically upon the closing of the initial public offering of the Issuer. F7 · derivative.expiration_date: The shares of Series C Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1.1869 basis automatically upon the closing of the initial public offering of the Issuer. F1 · ownership.nature: MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 17:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSeries B Convertible Preferred Stock · Derivative | 3,578,653 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · derivative · entry 6 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 0 Underlying: Class A Common Stock · 3,578,653 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: The shares of Series B Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F6 · price: The shares of Series B Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F6 · derivative.exercise_date: The shares of Series B Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F6 · derivative.expiration_date: The shares of Series B Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F1 · ownership.nature: MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 17:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 5,963,140 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · nonDerivative · entry 5 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 8,740,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F2 · ownership.nature: Consists of (i) 2,777,777 shares held of record by Fifteenth Investment Company LLC and (ii) 5,963,140 shares held of record by Thirty Fifth Investment Company LLC. Both Fifteenth Investment Company LLC and Thirty Fifth Investment Company LLC are wholly owned subsidiaries of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 17:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 745,392 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · nonDerivative · entry 3 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 7,062,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F1 · ownership.nature: MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 17:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 2,738,824 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · nonDerivative · entry 2 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 6,317,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: The shares of Series C Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1.1869 basis automatically upon the closing of the initial public offering of the Issuer. F1 · ownership.nature: MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 17:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 3,578,653 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 3,578,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: The shares of Series B Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer. F1 · ownership.nature: MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 17:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | PurchaseClass A Common Stock | 2,777,777 | $18.00 | $49,999,986.00 |
DisclosureSEC source: 0001387131-21-004685 · rxrx-form4_041621.xml · nonDerivative · entry 4 Mubadala Investment Co PJSC · CIK 0001704268 · 10% owner Mamoura Diversified Global Holding PJSC · CIK 0001419351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 2,777,777 F2 · ownership.nature: Consists of (i) 2,777,777 shares held of record by Fifteenth Investment Company LLC and (ii) 5,963,140 shares held of record by Thirty Fifth Investment Company LLC. Both Fifteenth Investment Company LLC and Thirty Fifth Investment Company LLC are wholly owned subsidiaries of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi. F3 · ownership.nature: On April 16, 2021, Fifteenth Investment Company LLC acquired 2,777,777 Class A Shares at a price of $18 per share in connection with Recursion Pharmaceutical, Inc.'s (the "Issuer") initial public offering. F4 · ownership.nature: Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any. F5 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| May 01, 2019 Filed May 14, 2019 18:24 UTC | GAIA, INC GAIA · Entity 2726 | OtherClass A Common Stock | 1,266,461 | $10.58 | $13,399,157.38 |
DisclosureSEC source: 0000947871-19-000369 · ownership.xml · nonDerivative · entry 2 Mubadala Investment Co PJSC · CIK 0001704268 · Former 10% holder MDC Capital (Cayman) Ltd · CIK 0001763537 · Former 10% holder Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: On May 1, 2019, in connection with fund reorganization activities, the shares previously beneficially owned by the Reporting Persons were contributed to MIC Capital Partners (Public) Parallel Cayman, LP ("MIC Capital") in a non-cash transaction at a value of $10.58 per share (the "Contribution"). Following the Contribution, the Reporting Persons no longer had beneficial ownership of any shares of the Issuer, but may be considered to have pecuniary interest (without control) in certain shares held by MIC Capital (which such number of shares would be less than 10% of the outstanding class of shares). F2 · shares: 1,266,461 shares were held of record by MDC Capital (Cayman) Limited ("MDC Capital (Cayman)"), as trustee for Fifty First Investment Company LLC. MDC Capital (Cayman) is a direct wholly owned subsidiary of MDC Capital LLC. MDC Capital LLC, MDC Capital (Cayman) and Fifty First Investment Company LLC are controlled subsidiaries of Mubadala Development Company PJSC. Mubadala Development Company PJSC is wholly owned by Mubadala Investment Company PJSC. F3 · price: On May 1, 2019, in connection with fund reorganization activities, the shares previously beneficially owned by the Reporting Persons were contributed to MIC Capital Partners (Public) Parallel Cayman, LP ("MIC Capital") in a non-cash transaction at a value of $10.58 per share (the "Contribution"). Following the Contribution, the Reporting Persons no longer had beneficial ownership of any shares of the Issuer, but may be considered to have pecuniary interest (without control) in certain shares held by MIC Capital (which such number of shares would be less than 10% of the outstanding class of shares). F3 · balance_after: On May 1, 2019, in connection with fund reorganization activities, the shares previously beneficially owned by the Reporting Persons were contributed to MIC Capital Partners (Public) Parallel Cayman, LP ("MIC Capital") in a non-cash transaction at a value of $10.58 per share (the "Contribution"). Following the Contribution, the Reporting Persons no longer had beneficial ownership of any shares of the Issuer, but may be considered to have pecuniary interest (without control) in certain shares held by MIC Capital (which such number of shares would be less than 10% of the outstanding class of shares). F2 · ownership.nature: 1,266,461 shares were held of record by MDC Capital (Cayman) Limited ("MDC Capital (Cayman)"), as trustee for Fifty First Investment Company LLC. MDC Capital (Cayman) is a direct wholly owned subsidiary of MDC Capital LLC. MDC Capital LLC, MDC Capital (Cayman) and Fifty First Investment Company LLC are controlled subsidiaries of Mubadala Development Company PJSC. Mubadala Development Company PJSC is wholly owned by Mubadala Investment Company PJSC. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:29 UTC | ADVANCED MICRO DEVICES INC AMD · Entity 2796 | OtherWarrant (right to buy) · Derivative | 75,000,000 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0000947871-19-000080 · ownership.xml · derivative · entry 3 Mubadala Investment Co PJSC · CIK 0001704268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 75,000,000 shares Expires 2020-02-29 F3 · price: The warrant was granted to a subsidiary of the Reporting Person as part of the consideration for a commercial agreement between the issuer and such subsidiary and were subsequently transferred to the Reporting Person by such subsidiary (see Exhibit 10.1 of AMD's Current Report on Form 8-K, filed on August 31, 2016). F2 · derivative.exercise_date: The warrant became exercisable with respect to 50,000,000 shares of common stock of the issuer upon issuance of the warrant, however did not become exercisable with respect to 25,000,000 shares of common stock of the issuer until August 30, 2017. Exercise of the warrant will be settled with proceeds from the sale of Common Stock detailed in Table I. F1 · ownership.nature: The shares are held on behalf of the Reporting Person by West Coast Hitech L.P., a Cayman Islands limited partnership wholly-owned and controlled by the Reporting Person. West Coast Hitech G.P., Ltd. is a Cayman Islands corporation wholly-owned and controlled by the Reporting Person that acts as the general partner of West Coast Hitech L.P. The business address of West Coast Hitech L.P. and West Coast Hitech G.P., Ltd. is P.O. Box 45005, Abu Dhabi, United Arab Emirates. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:29 UTC | ADVANCED MICRO DEVICES INC AMD · Entity 2796 | OtherCommon Stock | 75,000,000 | $5.98 | $448,500,000.00 |
DisclosureSEC source: 0000947871-19-000080 · ownership.xml · nonDerivative · entry 2 Mubadala Investment Co PJSC · CIK 0001704268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 75,000,000 F1 · ownership.nature: The shares are held on behalf of the Reporting Person by West Coast Hitech L.P., a Cayman Islands limited partnership wholly-owned and controlled by the Reporting Person. West Coast Hitech G.P., Ltd. is a Cayman Islands corporation wholly-owned and controlled by the Reporting Person that acts as the general partner of West Coast Hitech L.P. The business address of West Coast Hitech L.P. and West Coast Hitech G.P., Ltd. is P.O. Box 45005, Abu Dhabi, United Arab Emirates. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:29 UTC | ADVANCED MICRO DEVICES INC AMD · Entity 2796 | SaleCommon Stock | 34,906,166 | $23.43 | $817,851,469.38 |
DisclosureSEC source: 0000947871-19-000080 · ownership.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · ownership.nature: The shares are held on behalf of the Reporting Person by West Coast Hitech L.P., a Cayman Islands limited partnership wholly-owned and controlled by the Reporting Person. West Coast Hitech G.P., Ltd. is a Cayman Islands corporation wholly-owned and controlled by the Reporting Person that acts as the general partner of West Coast Hitech L.P. The business address of West Coast Hitech L.P. and West Coast Hitech G.P., Ltd. is P.O. Box 45005, Abu Dhabi, United Arab Emirates. Read SEC document |
| December 04, 2018 Filed May 14, 2019 18:24 UTC | GAIA, INC GAIA · Entity 2726 | PurchaseClass A Common Stock | 15,250 | $12.74 | $194,285.00 |
DisclosureSEC source: 0000947871-19-000369 · ownership.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · Former 10% holder MDC Capital (Cayman) Ltd · CIK 0001763537 · Former 10% holder Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,266,461 F1 · shares: The Reporting Person inadvertently failed to report the acquisition of these shares at the time of acquisition. F2 · ownership.nature: 1,266,461 shares were held of record by MDC Capital (Cayman) Limited ("MDC Capital (Cayman)"), as trustee for Fifty First Investment Company LLC. MDC Capital (Cayman) is a direct wholly owned subsidiary of MDC Capital LLC. MDC Capital LLC, MDC Capital (Cayman) and Fifty First Investment Company LLC are controlled subsidiaries of Mubadala Development Company PJSC. Mubadala Development Company PJSC is wholly owned by Mubadala Investment Company PJSC. Read SEC document |
| July 30, 2018 Filed Aug 2, 2018 01:36 UTC | ADVANCED MICRO DEVICES INC AMD · Entity 2796 | SaleCommon Stock | 22,000,000 | $19.33 | $425,150,000.00 |
DisclosureSEC source: 0000947871-18-000617 · ownership.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 109,906,166 F1 · ownership.nature: The shares are held on behalf of the Reporting Person by West Coast Hitech L.P., a Cayman Islands limited partnership wholly-owned and controlled by the Reporting Person. West Coast Hitech G.P., Ltd. is a Cayman Islands corporation wholly-owned and controlled by the Reporting Person that acts as the general partner of West Coast Hitech L.P. The business address of West Coast Hitech L.P. and West Coast Hitech G.P., Ltd. is P.O. Box 45005, Abu Dhabi, United Arab Emirates. Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 21:29 UTC | ADVANCED MICRO DEVICES INC AMD · Entity 2796 | SaleCommon Stock | 40,000,000 | $525,600,000.00 | $21,024,000,000,000,000.00 |
DisclosureSEC source: 0000947871-17-000614 · ss54103_4.xml · nonDerivative · entry 1 Mubadala Investment Co PJSC · CIK 0001704268 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 131,906,166 F1 · ownership.nature: The shares are held on behalf of the Reporting Person by West Coast Hitech L.P., a Cayman Islands limited partnership wholly-owned and controlled by the Reporting Person. West Coast Hitech G.P., Ltd. is a Cayman Islands corporation wholly-owned and controlled by the Reporting Person that acts as the general partner of West Coast Hitech L.P. The business address of West Coast Hitech L.P. and West Coast Hitech G.P., Ltd. is P.O. Box 45005, Abu Dhabi, United Arab Emirates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.